Cargando…
RUNX2-modifying enzymes: therapeutic targets for bone diseases
RUNX2 is a master transcription factor of osteoblast differentiation. RUNX2 expression in the bone and osteogenic front of a suture is crucial for cranial suture closure and membranous bone morphogenesis. In this manner, the regulation of RUNX2 is precisely controlled by multiple posttranslational m...
Autores principales: | Kim, Woo-Jin, Shin, Hye-Lim, Kim, Bong-Soo, Kim, Hyun-Jung, Ryoo, Hyun-Mo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080656/ https://www.ncbi.nlm.nih.gov/pubmed/32788656 http://dx.doi.org/10.1038/s12276-020-0471-4 |
Ejemplares similares
-
Post-Translational Regulations of Transcriptional Activity of RUNX2
por: Kim, Hyun-Jung, et al.
Publicado: (2020) -
Excessive osteoclast activation by osteoblast paracrine factor RANKL is a major cause of the abnormal long bone phenotype in Apert syndrome model mice
por: Shin, Hye‐Rim, et al.
Publicado: (2022) -
Peptidylarginine deiminase 2 plays a key role in osteogenesis by enhancing RUNX2 stability through citrullination
por: Kim, Hyun-Jung, et al.
Publicado: (2023) -
Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with RUNX1-RUNX1T1 Fusion
por: Yun, Jae Won, et al.
Publicado: (2019) -
First Case of ETV6–RUNX1 Fusion in Adult De Novo Acute Myeloid Leukemia Detected Using Targeted RNA Sequencing
por: Jeon, Seong-Jun, et al.
Publicado: (2023)